SCHEMBL6155895

SCHEMBL6155895

NC(=O)Nc1cc(Cl)ccc1OCC(=O)N1[C@@H]2CC[C@@H]1CC(Oc1ccc(F)cc1)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 8/20 0.54
FPR3 P25089 1/20 0.54
GPR65 Q8IYL9 1/20 0.54
GPR35 Q9HC97 1/20 0.54
EPHX2 P34913 2/20 0.41
OPRK1 P41145 3/20 0.39
KCNH2 Q12809 3/20 0.39
OPRM1 P35372 2/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6155902 1.00 CCR1 (0.54) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6762090 1.00 CCR1 (0.54) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6763114 0.87 CCR1 (0.40) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6763101 0.87 CCR1 (0.40) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6765304 0.87 CCR1 (0.43) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6765302 0.87 CCR1 (0.43) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6156266 0.86 CCR1 (0.43) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6156258 0.86 CCR1 (0.43) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6758368 0.86 CCR1 (0.43) CCR1FPR3GPR65GPR35EPHX2
SCHEMBL6761287 0.86 CCR1 (0.41) CCR1FPR3GPR65GPR35EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063688-A1 Novel piperidine derivatives PFIZER INC. 2004-04-01 US claimed
EP-1525201-A1 BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR Pfizer Products Inc. (US) 2005-04-27 EP disclosed
US-20040063688-A1 Novel piperidine derivatives PFIZER INC. 2004-04-01 US disclosed
WO-2004009588-A1 BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR PFIZER PRODUCTS INC. (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063688-A1 Novel piperidine derivatives CCR1, CCR3, CCR2 CCR1 1/4885FPR3 43/4885GPR65 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.